PCYT2 Inhibitors
PCYT2 inhibitors belong to a class of chemical compounds designed to target and modulate the activity of the PCYT2 enzyme, which stands for Phosphatidylcholine CTP-transferase 2. PCYT2 is a key enzyme involved in the biosynthesis of phosphatidylcholine, a crucial component of cell membranes. Phosphatidylcholine is a phospholipid that is essential for maintaining the structural integrity and fluidity of cellular membranes. PCYT2 catalyzes the conversion of cytidine triphosphate (CTP) and phosphocholine (a precursor) into cytidine diphosphate choline (CDP-choline), which is a critical step in the biosynthesis of phosphatidylcholine. Inhibitors of PCYT2 are developed to interfere with its enzymatic activity, which can potentially disrupt the cellular processes involved in membrane formation and lipid metabolism.
The mechanisms by which PCYT2 inhibitors function can vary based on their chemical structures and binding properties. Some inhibitors may directly interact with the PCYT2 enzyme, preventing its catalytic activity or its binding to substrates like CTP and phosphocholine. Others may alter the enzyme's conformation or subcellular localization, affecting its ability to participate in phosphatidylcholine biosynthesis. By inhibiting PCYT2, these compounds have the potential to impact the cellular levels of phosphatidylcholine, which can influence membrane composition and properties. Ongoing research in this field aims to elucidate the precise mechanisms and downstream effects of PCYT2 inhibition, contributing to our understanding of its role in cellular biology and lipid metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Miltefosine | 58066-85-6 | sc-203135 | 50 mg | $81.00 | 8 | |
Miltefosine is a choline analogue that competitively inhibits PCYT2 by mimicking its natural substrate, choline. This inhibition disrupts the biosynthesis of phosphatidylcholine, a key component of cell membranes. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
D609 is a tricyclodecan-9-yl-xanthogenate that non-competitively inhibits PCYT2. It alters the enzyme's conformation, thus reducing its activity in phospholipid biosynthesis. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine, an alkylphospholipid, indirectly inhibits PCYT2 by interfering with cellular signaling pathways that regulate PCYT2 activity, particularly in lipid metabolism and cell proliferation. | ||||||
Edelfosine | 70641-51-9 | sc-507459 | 5 mg | $216.00 | ||
Edelfosine is a synthetic ether lipid that inhibits PCYT2 indirectly. It disrupts lipid rafts in cellular membranes, impacting PCYT2 localization and function. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $72.00 $206.00 $290.00 | 9 | |
C75 is a fatty acid synthase inhibitor that indirectly affects PCYT2 by altering fatty acid metabolism, which is crucial for the synthesis of phosphatidylcholine. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
Fumonisin B1 is a mycotoxin that inhibits ceramide synthase, leading to changes in sphingolipid metabolism that indirectly influence PCYT2 activity. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin indirectly inhibits PCYT2 by blocking N-linked glycosylation, impacting several pathways including those related to lipid metabolism and PCYT2 function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus, indirectly influencing PCYT2 activity by altering the intracellular transport and localization of lipids and enzymes involved in phospholipid synthesis. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
Triacsin C inhibits long-chain acyl-CoA synthetase, thereby indirectly affecting PCYT2 activity by reducing the availability of fatty acyl-CoA, a critical substrate for phosphatidylcholine synthesis. | ||||||